Compare AstraZeneca plc (AZN) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Global X SuperDividend ETF — how do they compare? AstraZeneca plc trades at $168.14 (market cap $253.13B), while Global X SuperDividend ETF trades at $24.82. The key difference: AstraZeneca plc pays a 1.92% dividend while Global X SuperDividend ETF pays none, and Global X SuperDividend ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SDIV | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $26.34 |
52-Week Low | $137.44 | $22.90 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
SDIV trades at $24.52, down 0.33% today, with a neutral technical signal overall. The ETF maintains a consistent dividend payout of $0.18 per share, with recent distributions in May and June 2026. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance cluster around $24-$25. Recent news highlights SDIV's appeal for income investors seeking diversification from tech-heavy portfolios.
SDIV offers investors exposure to high-yield global equities with minimal technology exposure, providing diversification benefits. The 9.29% yield remains attractive for income-focused portfolios, though the fund's heavy weighting in financials and energy sectors introduces sector concentration risks. Current technical positioning suggests limited near-term price movement potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
